EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSDNOG00000014989
Gene Symbol: GABBR2
4 Cross references
208 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSDNOG00000045568
Gene Symbol: GLP1R
2 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSDNOG00000016035
Gene Symbol: GLP2R
4 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSDNOG00000015156
Gene Symbol: GCK
2 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSDNOG00000035198
Gene Symbol: GBA1
2 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSDNOG00000045020
Gene Symbol: GRIA1
2 Cross references
325 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSDNOG00000012699
Gene Symbol: GRIA2
4 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSDNOG00000000650
Gene Symbol: GRIA3
4 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSDNOG00000035874
Gene Symbol: GRIA4
4 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSDNOG00000010464
Gene Symbol: GRIN2A
2 Cross references
295 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSDNOG00000009078
Gene Symbol: GRIN2C
2 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSDNOG00000035036
Gene Symbol: GRIN2D
3 Cross references
280 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).